Business
Veru Announces Appointment of Dr. David D. Ho as Chairman of its Infectious Disease Scientific Advisory Board
MIAMI. FL, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and
About this update from Veru Inc.
[{"type":"text","content":"MIAMI. FL, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced the appointment of David D. Ho, M.D., a trailblazer of infectious disease viral research and therapeutic development, as Chairman of its Scientific Advisory Board (SAB). “Today’s appointment of Dr. Ho as Chairman of Veru’s SAB illustrates our commitment to building a team of scientific experts to support our goal of developing and delivering life-saving therapies to patients with COVID-19 and other viral ARDS-related diseases,” said Mitchell Steiner, M.D., Chairman, President, and Chief Executive Officer of Veru. “Dr. Ho’s exemplary scientific contributions to the field, historically in HIV/AIDS and more recently in COVID-19, ideally position him to help shape the clinical development strategies of our expanding infectious disease program.” David D. Ho, M.D., is the Founding Scientific Director of the Aaron Diamond AIDS Research Center and the Clyde and Helen Wu Professor of Medicine at Columbia University Irving Medical Center, a Member of The National Academy of Medicine, as well as a Member of The American Academy of Arts & Sciences, and a Fellow of The American Association for the Advancement of Science. He received his M.D. from Harvard Medical School and has received fourteen honorary doctorates over the course of his career. In his noteworthy research, Dr. Ho discovered the nature of HIV replication, and the resulting innovative combination therapy remarkably enabled patients to manage this disease. In 1996, Dr. Ho was named TIME magazine’s Man of the Year based on his groundbreaking research and treatments, which provide hope to millions of patients in the daunting fight against HIV. In addition, Dr. Ho is leading a multi-disciplinary team of physicians, scientists, and engineers to advance the development of new drugs that target SARS-CoV-2 mutants. To date, his team at Columbia University has identified one of the broadest and most potent panels of antibodies against SARS-CoV-2. “I am thrilled to join Veru’s SAB as Chairman while their team works diligently to prepare for the potential commercialization of sabizabulin, a novel microtubular disruptor, for the treatment of hospitalized adult COVID-19 pa...